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Background: Previous studies have shown the importance of paying attention to lay peoples’ interpretations of risk
of disease, in order to explain health-related behavior. However, risk interpretations interplay with social context in
complex ways. The objective was to explore how asymptomatic patients with high cholesterol interpret risk of
cardiovascular disease.
Methods: Fourteen patients with high cholesterol and risk of cardiovascular disease were interviewed, and patterns
across patient accounts were identified and analysed from an ethnographic approach.
Results: Information from the general practitioner about high cholesterol and risk of cardiovascular disease was
reinterpreted in everyday social life. The risk associated with fatty foods was weighed against the pleasures of social
and cultural events in which this type of food was common and cherished.
A positive mindset was applied as a strategy to lower the risk of having high cholesterol, but knowledge about risk
was viewed as a cause of anxiety and self-absorption, and this anxiety made the body susceptible to disease,
hampering the chances for healthy life.
Conclusion: Interpretations of high cholesterol and risk of cardiovascular disease are embedded in social relations
and everyday life concerns. This should be addressed in general practice in preference-sensitive cases about
risk-reducing medication.
Trial registration: ClinicalTrials.gov: NCT01187056
Keywords: Risk perception, Cardiovascular disease, High cholesterol, Qualitative researchBackground
Cardiovascular disease accounted for 30% of all deaths
in 2008 and it is the number one cause of death world-
wide [1]. High cholesterol is a well-defined risk factor
for cardiovascular disease, and it is associated with un-
healthy diet and lack of exercise [2]. High cholesterol
can be lowered by lifestyle change combined with
cholesterol-reducing medication [3,4].
However, up to half of all patients prescribed with
cholesterol-reducing medication stop treatment within 6
months, with a further decline after one year [5,6]. The* Correspondence: pia. kirkegaard@alm.au.dk
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distribution, and reproduction in any mediumdecline is most prominent in patients with no bodily per-
ceptible symptoms of cardiovascular disease. Short-term
cholesterol-reducing medications have no documented
health benefits and discontinuation of cholesterol-
reducing medication or on/off use is unwanted from
individual and health service perspectives [7].
The reasons for the non-adherence/discontinuation of
cholesterol-reducing medication have been explored [8-12].
The studies report that epidemiological knowledge about
risk of disease, conveyed by doctors, may be little under-
stood by patients. Efforts have been made to reduce the
proportion of patients who feel uncertain about the deci-
sion to engage in medical preventive treatment for as long
as the general practitioner (GP) prescribes, but results
about the effect on adherence remain inconclusive [13].
However, everyday life experiences, risk interpretations andtral Ltd. This is an Open Access article distributed under the terms of the
/creativecommons.org/licenses/by/2.0), which permits unrestricted use,
, provided the original work is properly cited.
Table 1 Patient characteristics
Alias Age Marital status Co-morbidity
Ivan 61 Widower Pre-diabetes
Judith 60 Married None
Beth 65 Married (Kent) None
Kent 65 Married (Beth) None
Christian 67 Married (Ulla) None
Ulla 64 Married (Christian) Diabetes
Mary 61 Married (Frank) Familial hypercholesterolemia
Frank 62 Married (Mary) None
Laura 66 Married None
Christina 61 Married Diabetes
Tom 61 Married Pre-diabetes
Karen 70 Widow Stroke
Ursula 24 Single Familial hypercholesterolemia
Kurt 59 Married Diabetes
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been little explored. Anthropological and sociological stud-
ies have shown the importance of exploring people’s inter-
pretations of health and risk as part of ongoing social
processes, in which different rationalities for action are
used in interpretations about different matters [14-20]. De-
cisions to continue or stop risk-reducing medication are
embedded in everyday life concerns which form a back-
ground for the patients’ deliberations about risk of the dis-
ease and strategies to approach that risk.
The aim of this study was to explore how cholesterol-
reducing medication and risk of cardiovascular disease are
interpreted by asymptomatic patients with high choles-
terol. The following research questions were addressed:
What is the relationship between risk of cardiovascular
disease and everyday life concerns? How is the risk of hav-
ing high cholesterol weighed against other risks or con-
cerns? What is the role of the GP in relation to this?
Methods
Participants and recruitment
The qualitative study presented in this paper is a part of
the RISAP study – A Complex Intervention in Risk
Communication and Shared Decision-Making in Gen-
eral Practice [21,22]. The aim of the RISAP study was to
develop risk information for patients at high risk of car-
diovascular disease, and to evaluate the effect on the
number of prescribed cholesterol-reducing medication.
Fourteen patients were recruited through five GPs
who had participated in focus group discussions in the
development of the RISAP study. The GPs were asked to
provide the interviewers (two trained social anthropolo-
gists) with the name and address of the last patients who
had entered their practices and fulfilled the following
criteria: 1) patients who had high cholesterol and high
or very high risk of cardiovascular disease according to
the Danish guidelines for prevention of cardiovascular
disease in general practice [23], 2) patients who had re-
ceived information about cholesterol-reducing medica-
tion as a preventive treatment option, and 3) patients
who had no manifest cardiovascular disease or symp-
toms of it. Fifteen patients were contacted by a letter
from the researchers with information about the study,
and 14 patients – 8 women and 6 men – gave oral con-
sent to participate in an interview without renumeration
(Table 1). They were interviewed individually (n=8) or
with their spouses (n=6), and the interviews were
supplemented with fieldnotes about the interviews. Each
interview lasted 1-2 hours and took place in the patients’
homes. Twelve out of 14 patients reported to take
cholesterol-reducing medication. The sample included
patients from both primary and secondary prevention of
cardiovascular disease, but at the time of the interview,
none of them had symptoms which they interpreted asrelated to high cholesterol or to cardiovascular disease.
The participants appear under pseudonyms in the paper.
The study was performed according to the Helsinki
Declaration [24]. It was notified to the Danish Data Pro-
tection Agency and collection of data was handled
according to their guidelines (journal no. 2007-41-1446).
The study was exempted from obligation of notification
for the Danish Scientific-Ethical Committee, but it
followed the ethical code of American Anthropological
Association [25]. The study was part of the RISAP study
which was registered at ClinicalTrials.gov: NCT01187056.
Analytic approach and data analysis
An ethnographic approach was used to support the
interplay between theory, methods and data in the ana-
lytical process [26]. Firstly, the literature about risk per-
ception of patients at high risk of future disease was
reviewed by the first author, and social theories about
risk perception in the studies were discussed among the
researchers. Secondly, the theories helped frame ques-
tions for a semi-structured interview guide [27]. The fol-
lowing themes were included: experiences with risk of
cardiovascular disease (what is it like to have it?); inter-
pretations of risk of cardiovascular disease (what is it?),
risk negotiations (what did the GP say to you about it,
how did you respond, what did you tell your family and
friends, and how did they respond?). Each interview was
transcribed verbatim into text within few days after it
was performed, and handwritten fieldnotes were typed
up. The texts were put into a computer-based standard
text editor with tracked changes and thus discussed
among the researchers to jog the analytic process. The
first interviews drew our attention to the fact that the
patient accounts revolved explicitly around high cholesterol,
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was refined accordingly by adding questions about high
cholesterol to the themes mentioned above. Thirdly, a
preliminary analysis was agreed upon by the researchers,
and finally, the identified themes were approached from
theoretical perspectives to strengthen and contextualise
the findings in literature about risk. We chose to use the
notion of risk interpretation in the paper, in order to
underline the focus on the social aspect of risk. The cap-
ital letters in parentheses refer to the quotes in Table 2.
Results and discussion
Several participants suggested that high cholesterol was
caused by a certain lifestyle with fatty foods and lack of
exercise, and in some cases by genetic disposition (A,D).
Most of the participants, however, reported to have
healthy eating habits themselves - at least on weekdays.
They stressed the significance of indulging fatty foods as
part of a social event, i.e. eating together with family and
friends and enjoying each other’s company while appre-
ciating taste and composition and paying compliments
to the host. The fatty foods, associated with cardiovascular
risk by the participants, were only one aspect in the social
events. The fatty foods were appreciated because of the
well-known tastes and the traditions that surrounded
them. Thus, the risk associated with fatty foods was
weighed against the pleasures of social and cultural events
in which this type of food was common and cherished.
Some partipants argued that a ‘positive’ or embracing
attitude to life should accompany the focus on risk (F).
An embracing attitude implied appreciation of pleasur-
able matters in everyday life, combined with less concern
about natural bodily sensations or symptoms, which are
well-known and common in older people (B). In this
view, knowledge about risk caused anxiety and self-
absorption, and this anxiety made the body susceptible
to disease, hampering the chances for healthy life. Some
participants emphasized a non-correlation between high
cholesterol and the general health of the individual; if a
person considered himself a ‘healthy person’, high chol-
esterol represented minor risk or danger. In this view, a
healthy life style could even outweigh the risk of having
high cholesterol (E,F). However, most of the patients
saw the cholesterol-reducing medication as as a valid re-
sponse to high cholesterol, although they also stressed
the individual responsibility to eat sensibly and exercise
(C). Cholesterol expressed as a ’number’ was reported to
be easy to relate to in the absence of a bodily perceptible
sensations or symptoms. GPs were seen as brokers or in-
terpreters of important and complex knowledge about
the patient’s body, able to transform specific bodily
properties into numeric indicators.
Thus, the analysis revealed an underlying interpret-
ation of tight relations between body and mind, in whicha slowly deteriorating body at increasing risk of cardio-
vascular disease was upheld by social events, positive
mindsets, and cholesterol-reducing medication. High
cholesterol was related to the social event of eating, and
the social event was seen as a contributory reason to get-
ting a high cholesterol level and maintaining it. Worry
about high cholesterol would brace the medically defined
risk of cardiovascular disease, but high cholesterol did not
pose a high risk if maintaining a balance in physiological
and mental health. Cholesterol-reducing medication could
help lower the tangible numbers which were conveyed by
the GP, who would provide reassurance and supervision.
The findings in this study suggest that information
from the GP about high cholesterol and risk of cardio-
vascular disease was reinterpreted in everyday social life,
where people navigate according to different ‘concerns’
(not to be confused with worry), using rationalities for
action from different discourses [28]. In this theoretical
perspective, knowledge and norms are only two in many
premises for action; concerns related to experiences
often guide action [29]. They are used to explain the ap-
parent contradictions in people’s knowledge about a
given matter, and their actions; e.g. people navigate be-
tween different concerns to overcome the discrepancy be-
tween knowledge about the right thing to do according to
advice from health authorities (including the GP), and so-
cial relations that may imply risky behavior. Knowledge in
this perspective is a social practice in which issues about
cholesterol and cardiovascular disease is derived from
multiple sources, including social experience in everyday
life and medical/moral instructions about healthy living.
This study indicates the importance of not reducing the
patients’ reluctance towards the biomedical definition of
high cholesterol as a risk for cardiovascular disease to
non-adherence. Patients’ interpretations of high choles-
terol make sense in a social context, and risk reduction of
cardiovascular disease may not be acted upon as a primary
concern par excellence. In all, this suggests a more open
approach to the way patients make choices, in order to
understand that risk of cardiovascular disease may not be
a prominent concern in patients’ everyday lives.
It has been argued that GPs should address these con-
cerns in order to improve communication and shared
decision-making with patients about preventive treat-
ment benefits and risks [30]. Felde and Elverdam have
described how high cholesterol and risk of cardiovas-
cular disease is embedded in a contextual rationality,
contingent on the patient’s experience and social prac-
tice [31]. They urge GPs to pay attention to the way in
which the patients interpret high cholesterol and apply
meaning to it. They argue that general practice pro-
vides a particularly fruitful ground for addressing the
patients’ risk interpretations, experiences and social
practices.
Table 2 Quotes from participants unless otherwise indicated
A Judith: We are at risk here in our part of the world, in our culture…. In other places, the risk is different – environmental pollution in India or
Japan… that’s the way it is. It’s different. (…) Maybe it has something to do with our way of life in Denmark, you know, generally speaking. Many
Danes have it [high cholesterol], don’t they. (…) We live in abundance here in Denmark, you know….anyway, I really watch what I eat, I mean I
don’t eat that much sugar and fat.
A Ursula: We just eat everytime we meet. Pizzas, shawarmas…when you meet in the city on a café, or you go out at night… and we always end
up in a pizza bar somewhere at 3 a.m. Sure, it’s not that healthy for your body, but… I probably wouldn’t miss it.
A Ulla: You meet for a cosy chat, have something to eat… We hold on to the South Jutish cakes [det sønderjyske kaffebord], seven soft cakes,
seven hard cakes…. Sometimes up to 30 cakes…! […] Good, old-fashioned food for us.
A Christina: My diabetes, I have to be careful […] Gravy and pork cracklings… It’s extra important to enjoy every bite, when you think about it. In
the family…I mean, carrots and mineral water! [..?..] they would be very disappointed indeed.
B Judith: no, I’m not really afraid of it [high cholesterol]. But I find it annoying […]. Then I think to myself “OK you’re not as young as you were”.
You can’t… That’s how I think about it. Something will turn up as you get older. Something will turn up.
B Karen: well, you don’t get younger as years go by, that’s it, really. [..] You go into ’repair mode’, something happens in your body and you won’t
really feel it.
B Beth: [about husband Kent] he plays in the Old Boys League, and that’s one way to do it, so you don’t get a heart attack sitting in front of the
TV…. you’ll die on the football field (both laugh).
C Ivan: I trust the experts. If they tell me, that it is the right thing to do [take medication] – then it is the right thing to do. And as he said to me,
we cannot prolong your life. But you can still do something – maybe you can avoid a blood clot or something else. And then perhaps you could
have a better quality of life. But of course, you can’t take pills for everything and then live 15 years longer. He said, that’s not the point. He said
that the point is to reduce the numbers [cholesterol level]. That’s what it’s all about. Reducing the number.
C Kurt: he said it was OK, no danger ahead, and the medication keeps it low. […] He keeps an eye on me, my blood pressure, the fat in the blood,
all my numbers, so it won’t go too high. I can’t feel it, but they see it…the good and the bad fat in you. Not his fault I enjoyed my youth.
C Laura: you live your own life, it’s no one’s responsibility in the end, you know. He just keeps an eye on you, the nurse keeps an eye… […] it was
6.2 [turns over pages of a printout from the lab] and now its below 3, see, all is in place. You still have to eat… properly, or the medication won’t
work, for sure, I’m sure it won’t.
D [Fieldnotes] Mary, Frank, married, retired early after a life of hard physical work. Mary, tiny woman, swears that she never eats sweet things, Frank,
a sturdy man with a self-reported ‘sweet tooth’. Mary says her father died because his main coronary artery clotted, and her GP worried that Mary
might die from the same thing, if she doesn’t take her cholesterol-reducing medication. In both Mary’s and Frank’s families, many members have
died from blood clots, but Mary thinks she has ‘a certain kind of cholesterol’, different from that of Frank’s. [Quote] Mary: slim people get it too.
One of our friends… he is quite slim. And his cholesterol is very high indeed. It has nothing to do with obesity.
D Tom: No surprise, really, if your dad had a stroke at 40…. or if you were extremely overweight….then you can have someone stitch your lips
together [laugh] but in those cases, medication is probably not even enough…. In the end, it’s different, really, when it’s not running in the
family, and you live a healthy life and feel OK and fit. It’s not that complicated. […] You do what you can do, move your body, take the stairs […]
I don’t think that good cholesterol is dangerous, only to some people.
E [Fieldnotes] Kent, Beth, 65 years old, retired, unskilled labour. Beth’s cholesterol level is too high, takes medication. Kent had a health check 14
days ago.
[Interview dialogue]
Kent: Then, mine was really a bit too high, too.
Interviewer: what did she [the GP] say to you?
Kent: she said ‘it’s a bit too high.’ Then she said ‘what should we do about that?’ Then I said ‘we don’t do any damn thing about it’.
Interviewer: what did she say then?
Kent: you know, I eat a herring every day!
Beth (interrupting) [she said] we should try to lose some weight at Christmas time.
Kent: we’ll have to give it another go.
Interviewer: so you’ll just try again?
Kent: Yes! I won’t take medication to prevent disease.
Interviewer: no..?
Kent: I only want medication if something is wrong with me.
Interviewer: what did she say, then? Why…?
Kent: I don’t want a load of trash in me. I’m a natural kind of guy!
[…]
Interviewer: what if it turns out that you really need cholesterol-reducing medication?
Kent: well, it has to be absolutely necessary. Because, as I said before, I won’t take medication to prevent disease. I’d rather have another herring.
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Table 2 Quotes from participants unless otherwise indicated (Continued)
Beth: [laughing] well, another herring won’t necessarily lower it.
Interviewer: but what do you think it [herring] will prevent?
Kent: well, I don’t know.. what is it supposed to prevent?
Beth: well, cardiovascular disease and… that’s it.
Kent: yes, but..there’s nothing wrong with me. My blood pressure is fine. I have no diabetes even though it runs in the family. My mother’s
brother whom I never knew, died of diabetes in the 30’ies or 40’ies or whenever the hell it was. 1940. And my mother died of diabetes. And my
sister died of diabetes.
E Christian: I said to him that….. I’m not really… fond of taking pills. I thought that we should wait and see.
Interviewer: and this happened 5 or 6 years ago…?
Christian: yes, and then later on the pursuaded me to try it.
Interviewer: OK. What did he say?
Christian: Well… he said that… I might get… blood clots and stuff if I didn’t do something.
Interviewer: OK. Has anyone in your family had a blood clot?
Christian: Yes. I have a brother who is paralysed on one side..
Interviewer: Does it frighten you to think about that?
Christian: oh no. Not the least.
Interviewer: when did your GP tell you to try cholesterol-reducing medication?
Christian: well, he wanted me to start it when I went to see him. Every single time for the last… 2 or 3 years. Until I gave in.
Interviewer: what did he say to make you…[give in]?
Christian: he said…well, actually I don’t remember, apart from him threatening me… saying that I could risk getting a blood clot too.
Interviewer: did he tell you about your cholesterol level, what your numbers were, and stuff?
Christian: well, I think it was about 6 at the time. And he wanted it to be lower than that.
(…)
Christian: It is unhealthy from my point of view. It is not natural. And I can’t see the point in taking it as long as I am not ill.
Interviewer: but you do take it anyway…?
Christian: I do, yes.
Interviewer: Why?
Christian: Well, uhm, I am under pressure.
Ulla: come on, it’s not like that.
F Kurt: In the end, all that fuss about blood sugar and fat on your belly… or bum, what is it… maybe you should start focusing a bit on other
things. Appreciate your friends, take some time off, see all the good things you have in your life. Be a bit positive, for God’s sake, it won’t kill
you…. Who invented medicine, that’s my point.
F Kent: we are positive people. Positive people live longer. They really do […] Negative things come out of the blue. You shouldn’t pursue them.
F [Field notes] Judith, 60, retired school teacher, adverse bodily sensations, interprets them as side-effects. Sensations connected to awareness
about the potential side-effects as described in patient information leaflet.
[Quote] Judith: I admit that it causes a lot of anxiety. It really does. All the different options. They cause a lot of anxiety. And perhaps sometimes it
makes you focus a little bit too much on yourself. A bit anxious. You feel fine, right. That’s one aspect to it. It doesn’t make us happier – and
perhaps happiness is the best life-prolonging medicine you can get…Don’t you think? [laugh].
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at risk of cardiovascular disease [32]. They found that
being diagnosed with hypertension constituted a bio-
graphical disruption, and patients with hypertension
interpreted their condition as a chronic disease. In our
study, we found no direct expressions of high cholesterol
as a disease, and having high cholesterol was not
interpreted as a major disruption in life. However, high
cholesterol was in some ways acted upon as if it had a
certain materiality – it was ‘real’ even though it wasimperceptible, due to fact that it can be measured in nu-
merical form.
Limitation
The interview as method allows the researchers to gain
access to the participants’ accounts of their actions and
the meaning they apply to them, but not to the actions
themselves except for the ones enacted during the inter-
view [33]. Thus, it was not possible to observe ‘lived risk’
in the study, only to gain access to accounts about
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quest about recruiting participants for the interview study,
and they provided us with one to four patients each. We
assumed greater variance between the interviewed partici-
pants than between the GPs who recruited them, which
was confirmed by the fact that each of the interviewed
couples with high cholesterol had the same GP, and yet
they had diverse interpretations of cardiovascular disease
and the use of cholesterol-reducing medication.
Conclusion
This study explored how asymptomatic patients with
high cholesterol interpreted risk of cardiovascular dis-
ease. The research question was triggered by the obser-
vation that up to half of all asymptomatic patients with
high cholesterol who initiate cholesterol-reducing medi-
cation, stop treatment after 6 months, with a further de-
cline after 1 year. The study illustrates how patients
accepted, opposed or pondered about the cholesterol-
reducing medication as a proper response to lowering
the risk of cardiovascular disease. It also showed that the
GP plays a significant role in providing supervision of
the cholesterol level. However, patients’ interpretations
of high cholesterol and risk of cardiovascular disease are
embedded in social relations and everyday life concerns
which should be addressed by the GP during consulta-
tions about cholesterol-reducing medication as a treat-
ment option.
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